Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORTEN-2: 7 vs 14 Days of Antibiotics for P. aeruginosa Bacteremia
NCT05210439Phase 4Active, not recruiting
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Apr 2022
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Pseudomonas aeruginosa bacteremia (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Probability of achieving better DOOR/RADAR score. Started Apr 2022; status: active, not recruiting.
02
Conditions
Pseudomonas aeruginosa bacteremia
Beyond the preview
Go deeper on NCT05210439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210439.